The Future Design of Cancer Patient Advocacy is Here!

 

Cancer patient advocacy is undergoing a transformative shift as healthcare continues to evolve, making it more crucial than ever to ensure patients receive not just treatment but compassionate, personalized care. This pivotal change is the focus of the latest episode of “Healthcare Rethink,” where host Brian Urban looks at the future of cancer patient advocacy with Arif Kamal MD, MBA, the Chief Patient Officer at the American Cancer Society (ACS).

Dr. Kamal shares his journey from a bereaved son to a leading voice in oncology and patient advocacy. He emphasizes the importance of extending life and enhancing the quality of those additional days. The conversation covers critical aspects of the evolving landscape of cancer care, including integrating of personalized therapies, addressing social determinants of health, and the innovative use of technology like the ACS Cares app to meet patients where they are.

For those eager to understand how cancer patient advocacy is pushing the boundaries of traditional care, this episode offers a glimpse into a future where reducing suffering and improving the quality of life are at the heart of cancer care. Tune in to learn how the ACS drives change and what lies ahead in the ongoing fight against cancer.

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More